ID: ALA5181802

Max Phase: Preclinical

Molecular Formula: C27H45F3O2

Molecular Weight: 458.65

Representations

Canonical SMILES:  C[C@H](CC[C@](C)(O)C(F)(F)F)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C

Standard InChI:  InChI=1S/C27H45F3O2/c1-17(10-13-26(5,32)27(28,29)30)20-8-9-21-19-7-6-18-16-23(2,31)14-15-24(18,3)22(19)11-12-25(20,21)4/h17-22,31-32H,6-16H2,1-5H3/t17-,18-,19+,20-,21+,22+,23+,24+,25-,26+/m1/s1

Standard InChI Key:  XUIXYHLPAUINEV-TTYBACRPSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 458.65

Molecular Weight (Monoisotopic): 458.3372

AlogP: 7.13

#Rotatable Bonds: 4

Polar Surface Area: 40.46

Molecular Species: NEUTRAL

HBA: 2

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 2

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 11.41

CX Basic pKa:

CX LogP: 6.48

CX LogD: 6.48

Aromatic Rings: 0

Heavy Atoms: 32

QED Weighted: 0.47

Np Likeness Score: 1.97

References

1. Hill MD, Blanco MJ, Salituro FG, Bai Z, Beckley JT, Ackley MA, Dai J, Doherty JJ, Harrison BL, Hoffmann EC, Kazdoba TM, Lanzetta D, Lewis M, Quirk MC, Robichaud AJ..  (2022)  SAGE-718: A First-in-Class N-Methyl-d-Aspartate Receptor Positive Allosteric Modulator for the Potential Treatment of Cognitive Impairment.,  65  (13.0): [PMID:35785990] [10.1021/acs.jmedchem.2c00313]

Source

Source(1):

• Scientific Literature